Fungal infections account for more than 140 million cases of severe
and life-threatening conditions each year, causing approximately 1.7
million deaths annually. Candida albicans and related species are the most common human fungal pathogens,
causing both superficial (mucosal and cutaneous) and life-threatening
invasive infections (candidemia) with a 40–75% mortality rate.
Among many virulence factors of Candida albicans, morphological transition from yeast to hyphae, secretion of hydrolytic
enzymes, and formation of biofilms are considered to be crucial for
pathogenicity. However, the arsenals for the treatment against these
pathogens are restricted to only a few classes of approved drugs,
the efficacy of which is being compromised by host toxicity, fungistatic
activity, and the emergence of drug resistance. In this study, we
have described the development of a molecule, exhibiting excellent
antifungal activity (MIC 8 μg/mL), by tailoring acidic sophorolipids
with aryl alcohols via enzyme catalysis. This novel derivative, ASLdC3,
is a surface-active compound that lowers the surface tension of the
air–water interface up to 2-fold before reaching the critical
micelle concentration of 25 μg/mL. ASLdC3 exhibits excellent
antibiofilm properties against Candida albicans and other nonalbicans Candida species.
The molecule primarily exhibits its antifungal activity by perturbing
mitochondrial function through the alteration of the mitochondrial
membrane potential (MMP) and generation of reactive oxygen species
(ROS). The ROS damages fungal cell membrane function and cell wall
integrity, eventually leading to cell death. ASLdC3 was found to be
nontoxic in in vitro assay and nonhemolytic. Besides, it does not
cause toxicity in the C. elegans model.
Our study provides a valuable foundation for the potential of acidic
sophorolipid as a nontoxic, biodegradable precursor for the design
and synthesis of novel molecules for use as antimicrobial drugs as
well as for other clinical applications.